Activity

Using a new glycyrrhizin acid (GA)-eluting stent, this study aimed to characterize in vivo strut coverage and neointimal proliferation. Following a randomized procedure, twenty New Zealand White rabbits with atherosclerotic plaques were separated into three groups, each receiving a specific type of iliac artery stent: bare-metal stents (BMSs), rapamycin-eluting stents, or GA-eluting stents. The vessels, having undergone in vivo intravascular ultrasound (IVUS) assessment at 28 days, were subsequently prepared for scanning electron microscopy (SEM) and histological analysis. A four-week follow-up allowed for the comparison of stent and external elastic lamina (EEL) regions across the various groups. A comparative analysis revealed that rapamycin- or GA-eluting stents resulted in a reduction of neointimal area compared to bare metal stents (BMSs), though the GA-eluting stents displayed the lowest degree of reduction. The count of uncovered struts was higher in rapamycin-eluting stents than in GA-eluting stents or bare-metal stents. While endothelial coverage was similar for BMSs and GA-eluting stents, the level of endothelial nitric oxide synthase (eNOS) expression was dramatically higher in GA-eluting stents compared to both BMSs and rapamycin-eluting stents. Subsequently, GA-eluting stents demonstrated a pronounced promotion of re-endothelialization and arterial repair in a rabbit atherosclerotic model, in contrast to rapamycin-eluting stents. Finally, the data from this study demonstrate that the GA-coated stent was effective in inhibiting intimal hyperplasia and promoting re-endothelialization.

In traditional Chinese medicine, Aconite has been a significant treatment for diarrhea for many millennia. Whether the anti-diarrheal action of aconite aqueous extract (AA) is associated with regulation of gut microbiota or bile acid metabolism is currently undetermined. This research aimed to validate whether AA’s anti-diarrheal efficacy is achieved through modulation of gut microbial communities and bile acid transformations. In a mouse model of diarrhea, the therapeutic impact of AA was quantified through measurements of body weight, stool water content, diarrhea severity, intestinal transit rate, colon tissue examination, and colon tissue immunochemical analysis. Besides this, a high-throughput 16S rRNA sequencing method was used to probe the effect of AA on the gut microbiota, and a targeted metabolomics approach was applied to evaluate the effects of AA on bile acid metabolism. AA treatment yielded a reduction in fecal water content and diarrhea scores, a decrease in colon pathologies and intestinal transit rate. The consequence was an increment in the AQP3 and AQP4 content in the colon. Additionally, AA demonstrated a capability to govern the gut’s microbial community. mth1 signal Richness, determined via ACE and Chao1 indices, increased. Community structure alterations in the gut microbiota were evident via PCA, PCoA, and NMDS. Increases were seen in the relative abundance of norank f Muribaculaceae, Ruminococcus, Lachnospiraceae NK4A136 group, Prevotellaceae UCG-001, and norank f norank o Clostridia UCG-014; in contrast, a decrease was noted in the relative abundance of Escherichia-Shigella, unclassified f Ruminococcaceae, Ruminococcus torques group, and Parasutterella. Significantly, AA substantially amplified fecal TCA (a primary bile acid) and DCA, LCA, GDCA, dehydro-LCA, and 12-keto-LCA (secondary bile acids), subsequently restoring BA homeostasis. Furthermore, AA augmented the proportions of DCA to CA, DCA to TCA, and LCA to CDCA, while diminishing the proportions of TLCA to LCA, GLCA to LCA, and TUDCA to UDCA. AA’s capacity to mitigate diarrhea is correlated with its ability to reinstate gut microbiota and its role in regulating bile acid metabolism. The findings of this study provide a framework for the application of AA in managing diarrhea.

As a traditional Chinese medicine, baicalein, a 56,7-trihydroxyflavone, demonstrates multiple pharmacological and biological activities, including the noteworthy anti-inflammatory and anti-fibrotic effects. However, a therapeutic role for baicalein in alleviating peritoneal fibrosis has not been observed in any studies. Utilizing network pharmacology and molecular docking, this study investigated the potential role and mechanisms by which baicalein alleviates peritoneal fibrosis in individuals undergoing peritoneal dialysis. Both animal models and cultured human mesothelial cell lines were used to validate the results. Network analysis predicted nine intersection genes among baicalein targets and the human peritoneum RNA-seq dataset, encompassing four encapsulating peritoneal sclerosis samples and four control samples. The peritoneum with encapsulating peritoneal sclerosis exhibited higher levels of MMP2, BAX, ADORA3, HIF1A, PIM1, CA12, and ALOX5 compared to normal control peritoneum. This might make them important molecular targets for baicalein in addressing peritoneal fibrosis. Through KEGG and GO enrichment analyses, baicalein’s capacity to combat peritoneal fibrosis was determined to be through its influence on cell proliferation, inflammatory reactions, and the AGE-RAGE pathway. Analysis via molecular docking highlighted a significant potential for baicalein to bind to MMP2, consistent with the predictive model. Our findings, using a mouse model of peritoneal fibrosis induced by intraperitoneal injection of 425% glucose dialysate, showed that baicalein treatment significantly ameliorated peritoneal fibrosis. This improvement was reflected in reduced collagen deposition, decreased expression of -smooth muscle actin and fibronectin proteins, and decreased peritoneal thickness. This effect might be due to decreased MMP2 expression, suggesting baicalein’s possible therapeutic utility for peritoneal dialysis-related fibrosis.

Post-surgical dental implant pain is generally addressed with non-opioid pain relievers, such as nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen. The analgesic efficacy of over-the-counter doses of non-steroidal anti-inflammatory drugs and acetaminophen in implant patients remains comparatively unknown. A comparative study was performed to analyze the effects of naproxen sodium and acetaminophen regarding pain relief and anti-inflammation, after one or two dental implants were surgically placed. In a double-blind, randomized study design, fifteen adult patients were given either naproxen sodium (a 440 mg loading dose followed by 220 mg every eight hours) or acetaminophen (1000 mg every six hours, with a maximum daily dose of 3000 mg) for three days post-implantation. Pain assessments, using a 0-10 scale, were conducted every twenty minutes for six hours subsequent to the administration of the study medication. A 50 mg dose of Tramadol was provided as a rescue medication. Pre-surgery and at various postoperative time points (0, 1, 2, 4, 6, 24, and 72 hours), plasma and gingival crevicular fluid (GCF) were collected to assess interleukin (IL)-6, IL-8, and IL-1. Patients treated with naproxen sodium showed a considerably lower pain score than those treated with acetaminophen, revealing a statistically significant difference. Surgical intervention triggered a rise in plasma and gingival crevicular fluid inflammatory mediator levels, which approached pre-operative values by 72 hours. A comparison of plasma IL-6 levels six hours after surgery revealed a significantly lower value in patients administered naproxen sodium than in those given acetaminophen. No distinctions were noted in the concentrations of inflammatory mediators present in gingival crevicular fluid across the various treatment groups. Variations in inflammatory mediator concentrations in plasma and gingival crevicular fluid were correspondingly related to the number of implants placed and the body mass index (BMI). Post-operative pain and systemic inflammation were significantly better managed after the insertion of one or two dental implants using naproxen sodium, in contrast to acetaminophen’s efficacy. Further investigation is required to ascertain the applicability of these findings to more intricate implant procedures and the impact they have on clinical outcomes after implant insertion. ClinicalTrials.gov, an important platform for clinical trial registration, promotes data transparency, facilitating access to research information. Concerning the identifier, it is NCT04694300.

Gastric cancer (GC), a prevalent malignant tumor, typically carries a grim prognosis. Combination therapies potentially extend the lifespan of patients diagnosed with GC. Despite the powerful inhibitory effects of acacetin, a flavonoid, on multiple cancer cell types, the underlying mechanisms remain unclear. The use of network pharmacology and RNA sequencing predicted the targets of acacetin, which were subsequently confirmed through drug affinity responsive target stability (DARTS), cellular thermal shift assay (CETSA), and molecular docking approaches. A study of acacetin’s biological functions in MKN45 and MGC803 cells encompassed TUNEL assays, crystal staining, and colony formation assays. Reverse experiments served to confirm the pathways that acacetin affected. The in vivo antitumor properties of acacetin were assessed in a subcutaneous tumor model derived from xenotransplantation. Amongst more than a dozen potential targets, EGFR was identified in this study as a protein which directly binds to acacetin. Besides that, acacetin influenced the degree to which the EGFR was phosphorylated. Within a controlled laboratory environment, acacetin facilitated the death of gastric carcinoma cells through apoptosis. Subsequently, EGFR agonists reversed the hindering influence of acacetin on the STAT3 and ERK pathways. Acacetin, when administered in vivo, diminished pEGFR protein expression in tumor tissue, contributing to a regression of GC xenograft tumors, without any noticeable toxicity. Our research findings indicate that acacetin directly impacts EGFR in GC cells. Acacetin’s inhibition of EGFR phosphatase function, both in vitro and in vivo, was instrumental in its antitumor effects.